A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy in Children and Young Adults with Classical Hodgkin Lymphoma


Full Title

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)


The purpose of this study is to evaluate the safety and effectiveness of combining pembrolizumab immunotherapy with chemotherapy in children and young adults newly diagnosed with early-stage classical Hodgkin lymphoma. Pembrolizumab takes the brakes off the immune response by targeting a protein called PD-1, enabling the immune system to detect and destroy cancer cells.

All patients in this study will receive initial chemotherapy with a combination of anticancer drugs. Patients who respond well will continue to receive standard chemotherapy and/or radiation therapy, while those whose cancer does not respond well will receive pembrolizumab in combination with chemotherapy followed by radiation therapy and then just pembrolizumab. The medications used in this study are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have early-stage classical Hodgkin lymphoma that has not yet been treated.
  • This study is for patients ages 3 to 25.

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.